GLP-1 RA and SGLT-2 inhibitors are the most recent addition to drug therapies that reduce morbidity and mortality in T2D and HF, and are effective across the spectrum of LVEF. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.